Medicare's prescription drug program: competition issues and cost trends
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York
Nova Publishers
[2014]
|
| Schriftenreihe: | Health care in transition series
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 |
| Beschreibung: | Includes index |
| Beschreibung: | 1 online resource |
| ISBN: | 9781634631532 1634631536 9781634631228 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043783410 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160920s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9781634631532 |9 978-1-63463-153-2 | ||
| 020 | |a 1634631536 |9 1-63463-153-6 | ||
| 020 | |a 9781634631228 |9 978-1-63463-122-8 | ||
| 035 | |a (ZDB-4-EBA)ocn894666750 | ||
| 035 | |a (OCoLC)894666750 | ||
| 035 | |a (DE-599)BVBBV043783410 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 368.42600973 |2 23 | |
| 245 | 1 | 0 | |a Medicare's prescription drug program |b competition issues and cost trends |c Gloria R. Pattinson, editor |
| 264 | 1 | |a New York |b Nova Publishers |c [2014] | |
| 264 | 4 | |c © 2014 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Health care in transition series | |
| 500 | |a Includes index | ||
| 505 | 8 | |a MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE | |
| 505 | 8 | |a APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D | |
| 505 | 8 | |a The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index | |
| 505 | 8 | |a The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr | |
| 650 | 7 | |a BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management |2 bisacsh | |
| 650 | 7 | |a Medical care, Cost of |2 fast | |
| 650 | 7 | |a Medicare |2 fast | |
| 650 | 7 | |a Pharmaceutical services insurance |2 fast | |
| 650 | 4 | |a Managed care plans (Medical care) / Management | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Wirtschaft | |
| 650 | 4 | |a Medicare |a Pharmaceutical services insurance |z United States |a Medical care, Cost of |z United States | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Pattinson, Gloria R. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Pattinson, Gloria R |t . Medicare's Prescription Drug Program : Competition Issues and Cost Trends |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029194470 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176615429636096 |
|---|---|
| any_adam_object | |
| author2 | Pattinson, Gloria R. |
| author2_role | edt |
| author2_variant | g r p gr grp |
| author_facet | Pattinson, Gloria R. |
| building | Verbundindex |
| bvnumber | BV043783410 |
| collection | ZDB-4-EBA |
| contents | MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr |
| ctrlnum | (ZDB-4-EBA)ocn894666750 (OCoLC)894666750 (DE-599)BVBBV043783410 |
| dewey-full | 368.42600973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 368 - Insurance |
| dewey-raw | 368.42600973 |
| dewey-search | 368.42600973 |
| dewey-sort | 3368.42600973 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04232nmm a2200553zc 4500</leader><controlfield tag="001">BV043783410</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160920s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634631532</subfield><subfield code="9">978-1-63463-153-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634631536</subfield><subfield code="9">1-63463-153-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634631228</subfield><subfield code="9">978-1-63463-122-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-EBA)ocn894666750</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)894666750</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043783410</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">368.42600973</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Medicare's prescription drug program</subfield><subfield code="b">competition issues and cost trends</subfield><subfield code="c">Gloria R. Pattinson, editor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Publishers</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Health care in transition series</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical care, Cost of</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicare</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical services insurance</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Managed care plans (Medical care) / Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wirtschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicare</subfield><subfield code="a">Pharmaceutical services insurance</subfield><subfield code="z">United States</subfield><subfield code="a">Medical care, Cost of</subfield><subfield code="z">United States</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pattinson, Gloria R.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="a">Pattinson, Gloria R</subfield><subfield code="t">. Medicare's Prescription Drug Program : Competition Issues and Cost Trends</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029194470</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043783410 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:35:00Z |
| institution | BVB |
| isbn | 9781634631532 1634631536 9781634631228 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029194470 |
| oclc_num | 894666750 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Publishers |
| record_format | marc |
| series2 | Health care in transition series |
| spelling | Medicare's prescription drug program competition issues and cost trends Gloria R. Pattinson, editor New York Nova Publishers [2014] © 2014 1 online resource txt rdacontent c rdamedia cr rdacarrier Health care in transition series Includes index MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast Managed care plans (Medical care) / Management Pharmacology Pharmacy Wirtschaft Medicare Pharmaceutical services insurance United States Medical care, Cost of United States USA Pattinson, Gloria R. edt Erscheint auch als Druck-Ausgabe Pattinson, Gloria R . Medicare's Prescription Drug Program : Competition Issues and Cost Trends |
| spellingShingle | Medicare's prescription drug program competition issues and cost trends MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast Managed care plans (Medical care) / Management Pharmacology Pharmacy Wirtschaft Medicare Pharmaceutical services insurance United States Medical care, Cost of United States |
| title | Medicare's prescription drug program competition issues and cost trends |
| title_auth | Medicare's prescription drug program competition issues and cost trends |
| title_exact_search | Medicare's prescription drug program competition issues and cost trends |
| title_full | Medicare's prescription drug program competition issues and cost trends Gloria R. Pattinson, editor |
| title_fullStr | Medicare's prescription drug program competition issues and cost trends Gloria R. Pattinson, editor |
| title_full_unstemmed | Medicare's prescription drug program competition issues and cost trends Gloria R. Pattinson, editor |
| title_short | Medicare's prescription drug program |
| title_sort | medicare s prescription drug program competition issues and cost trends |
| title_sub | competition issues and cost trends |
| topic | BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast Managed care plans (Medical care) / Management Pharmacology Pharmacy Wirtschaft Medicare Pharmaceutical services insurance United States Medical care, Cost of United States |
| topic_facet | BUSINESS & ECONOMICS / Insurance / Risk Assessment & Management Medical care, Cost of Medicare Pharmaceutical services insurance Managed care plans (Medical care) / Management Pharmacology Pharmacy Wirtschaft Medicare Pharmaceutical services insurance United States Medical care, Cost of United States USA |
| work_keys_str_mv | AT pattinsongloriar medicaresprescriptiondrugprogramcompetitionissuesandcosttrends |